Increased Hunger After Weight Loss Reflects Normal Appetite Peptide Adjustment, Not a Broken System | Research

The takeaway

After 17% weight loss, appetite-related peptide hormones and hunger levels in formerly obese adults matched those of never-obese people with similar body composition — suggesting normalization rather than dysfunction.

Hunger normalized to controls
After 17% weight loss maintained at one year, ghrelin and subjective hunger in formerly obese adults were no different from never-obese people of the same body composition

What the researchers found

After 17% body weight loss maintained at one year, reduced-obese adults showed increased hunger ratings and higher ghrelin secretion (both basal and postprandial) compared to their pre-weight-loss baseline. However, these appetite markers were not different from those of body-composition-matched nonobese controls, indicating normalization rather than compensatory overshoot.

Postprandial concentrations of active GLP-1, total peptide YY, and cholecystokinin remained lower in individuals with obesity at all time points compared to nonobese controls — both before and after weight loss. This suggests that blunted satiety peptide secretion is a feature of obesity itself rather than a consequence of weight loss.

Why it matters

This study challenges the prevailing narrative that weight loss triggers a permanent state of excessive hunger driven by hormonal changes. Instead, the data suggest that increased appetite after weight loss is simply the body recalibrating to match its new, lower weight — the same appetite levels that lean people naturally have. This is reassuring for weight loss maintenance and has implications for understanding why peptide-based appetite drugs like GLP-1 agonists are effective.

How the study worked

This controlled study enrolled 34 adults with obesity who underwent a dietary weight loss program, achieving 17% weight loss at week 13 and maintaining it at one year. They were compared to 33 nonobese controls matched for body composition. All participants underwent standardized meal tests with measurements of subjective appetite ratings and blood concentrations of multiple appetite-related peptide hormones: ghrelin, total PYY, PYY3-36, total and active GLP-1, and cholecystokinin. The weight-loss group was measured at baseline, week 13, and one year.

What this study cannot tell us

The sample size of 67 participants is moderate and may not capture the full range of individual variation in appetite hormone responses. The study measured peptide concentrations but did not assess receptor sensitivity, which could also change with weight loss. The one-year follow-up, while longer than many weight loss studies, may not capture very long-term hormonal adaptations. The control matching was based on body composition rather than randomization, which could introduce confounding variables.

How to read the evidence

This is a prospective controlled study with a one-year follow-up and body-composition-matched controls, representing moderate-quality evidence. The comprehensive panel of peptide hormone measurements strengthens the findings. However, it is not randomized, and the moderate sample size limits generalizability.

When this study was published

Published in 2020, this study is relatively recent and remains highly relevant as the field grapples with understanding long-term appetite regulation in the context of peptide-based obesity treatments.

The bigger picture

The explosion of GLP-1 receptor agonist drugs for obesity has highlighted the importance of appetite peptide hormones. This study provides important context: people with obesity already have blunted secretion of satiety peptides like GLP-1, PYY, and CCK, which may contribute to overeating. Drugs like semaglutide work by supplementing or mimicking these deficient peptide signals. The finding that weight loss alone doesn't fix this blunted secretion helps explain why pharmacological peptide-based intervention may be needed for long-term weight management.

Questions still open

Could the persistently blunted GLP-1 and PYY secretion in obesity be a cause rather than a consequence of excess weight?
Would GLP-1 receptor agonist therapy normalize satiety peptide responses in addition to its direct receptor effects?
Do different weight loss methods (diet vs. surgery vs. medication) produce different patterns of appetite peptide normalization?

Common questions

Does weight loss make you permanently hungrier?

This study suggests it doesn't — at least not in an abnormal way. While hunger and the hunger hormone ghrelin increased after weight loss, they matched the levels seen in naturally lean people of the same body composition. In other words, your appetite system adjusts to match your new body size, just like a lean person's appetite matches theirs. The increased hunger compared to your obese baseline is actually what normal appetite feels like at a lower weight.

Why are satiety peptides like GLP-1 lower in people with obesity?

The study found that people with obesity had consistently lower postprandial levels of GLP-1, PYY, and CCK — peptides that normally signal fullness after eating — compared to lean controls. This blunting persisted even after weight loss, suggesting it may be an underlying feature of obesity rather than something caused by excess weight. This finding helps explain why GLP-1 receptor agonist drugs like semaglutide are effective: they compensate for the body's insufficient production of natural satiety peptides.

Read the original research

Changes in the Homeostatic Appetite System After Weight Loss Reflect a Normalization Toward a Lower Body Weight.

The Journal of clinical endocrinology and metabolism, 105(7), e2538-46

View on PubMed ↗Publisher’s paper ↗

Citation

DeBenedictis, Julia Nicole; Nymo, Siren; Ollestad, Karoline Haagensli; Boyesen, Guro Akersveen; Rehfeld, Jens Frederik; Holst, Jens Juul; Truby, Helen; Kulseng, Bard; Martins, Catia. (2020). Changes in the Homeostatic Appetite System After Weight Loss Reflect a Normalization Toward a Lower Body Weight.. The Journal of clinical endocrinology and metabolism, 105(7), e2538-46. https://doi.org/10.1210/clinem/dgaa202